PURPOSE: This study was designed to determine whether human corneal endothelial (HCE) cells could regulate the activation of bystander T cells in vitro. METHODS: HCE cell lines were established from primary HCE cells. Target-activated T cells were used allogeneic T cells and Jurkat T-cell lines. As an additional target, T-cell clones from uveitis patients were established from aqueous humor via a limiting dilution. T-cell activation was assessed for proliferation by [(3)H]-thymidine incorporation, carboxyfluorescein succinimidyl ester incorporation, or IFNgamma production. Expression of co-stimulatory molecules on IFNgamma-treated corneal endothelial and non-treated cells was evaluated by flow cytometry, RT-PCR, or immunohistochemistry. Expression of co-stimulatory receptors on target T cells was evaluated by flow cytometry. Blocking antibodies was used to abolish the HCE-inhibitory function. RESULTS: HCE cells suppressed both in vitro proliferation and IFNgamma production by CD4(+) T cells via a cell contact-dependent mechanism. HCE constitutively expressed co-stimulatory molecules programmed death-ligand 1 (PD-L1) and PD-L2, and their expression was enhanced by IFNgamma. HCE efficiently inhibited the proliferation of Th1 cells that overexpressed PD-1 among various activated T-cell lines and clones established from patients with uveitis or corneal endotheliitis. A neutralizing mAb for PD-L1, but not PD-L2, blocked the suppressive effect of HCE on Th1 cells. CONCLUSIONS: HCE can impair the effector functions and activation of Th1 infiltrating CD4(+) T cells via the PD-1/PD-L1 interaction. The data support the hypothesis that corneal endothelium may contribute to maintenance of the privileged immune status of the anterior chamber of the eye by inducing peripheral immune tolerance.
PURPOSE: This study was designed to determine whether human corneal endothelial (HCE) cells could regulate the activation of bystander T cells in vitro. METHODS:HCE cell lines were established from primary HCE cells. Target-activated T cells were used allogeneic T cells and Jurkat T-cell lines. As an additional target, T-cell clones from uveitispatients were established from aqueous humor via a limiting dilution. T-cell activation was assessed for proliferation by [(3)H]-thymidine incorporation, carboxyfluorescein succinimidyl ester incorporation, or IFNgamma production. Expression of co-stimulatory molecules on IFNgamma-treated corneal endothelial and non-treated cells was evaluated by flow cytometry, RT-PCR, or immunohistochemistry. Expression of co-stimulatory receptors on target T cells was evaluated by flow cytometry. Blocking antibodies was used to abolish the HCE-inhibitory function. RESULTS:HCE cells suppressed both in vitro proliferation and IFNgamma production by CD4(+) T cells via a cell contact-dependent mechanism. HCE constitutively expressed co-stimulatory molecules programmed death-ligand 1 (PD-L1) and PD-L2, and their expression was enhanced by IFNgamma. HCE efficiently inhibited the proliferation of Th1 cells that overexpressed PD-1 among various activated T-cell lines and clones established from patients with uveitis or corneal endotheliitis. A neutralizing mAb for PD-L1, but not PD-L2, blocked the suppressive effect of HCE on Th1 cells. CONCLUSIONS:HCE can impair the effector functions and activation of Th1 infiltrating CD4(+) T cells via the PD-1/PD-L1 interaction. The data support the hypothesis that corneal endothelium may contribute to maintenance of the privileged immune status of the anterior chamber of the eye by inducing peripheral immune tolerance.
Authors: Andres Chang; Danielle Schlafer; Christopher R Flowers; Pamela B Allen Journal: Expert Opin Investig Drugs Date: 2017-12-24 Impact factor: 6.206
Authors: Iris Hecht; Amir Toporik; Joseph R Podojil; Ilan Vaknin; Gady Cojocaru; Anat Oren; Elizabeta Aizman; Spencer C Liang; Ling Leung; Yosef Dicken; Amit Novik; Nadav Marbach-Bar; Aziza Elmesmari; Clare Tange; Ashley Gilmour; Donna McIntyre; Mariola Kurowska-Stolarska; Kay McNamee; Judith Leitner; Shirley Greenwald; Liat Dassa; Zurit Levine; Peter Steinberger; Richard O Williams; Stephen D Miller; Iain B McInnes; Eyal Neria; Galit Rotman Journal: J Immunol Date: 2018-02-05 Impact factor: 5.422